EBM Technologies Incorporated AI Stock Analysis
EBM Technologies Incorporated (8409) AI Stock Analysis
EBM Technologies Incorporated
(TPEx:8409)
Weak financial performance from revenue volatility and negative cash flows is the main drag, reinforced by bearish technical signals; moderate valuation provides only partial support.
EBM Technologies Incorporated (8409) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- TWD 576.00M
- Dividend Yield
- ―
- Average Volume (3M)
- 8,627
- Price to Earnings (P/E)
- 47.4
- Beta (1Y)
- 0.30
- Revenue Growth
- -31.90%
- EPS Growth
- -73.49%
- Country
- TW
- Employees
- 150
- Sector
- General
- Sector Strength
- 55
- Industry
- Medical - Healthcare Information Services
EBM Technologies Incorporated Business Overview & Revenue Model
Company Description
Established in 1988 and headquartered in Taipei, Taiwan, EBM Technologies Incorporated is dedicated to developing and commercializing sophisticated software and integrated solutions for the global healthcare sector. The company's core offerings inclu...
EBM Technologies Incorporated Financial Statement Overview
Summary
Mixed results with volatile revenue, sharply negative cash flows, and thin margins outweighing a stable low-leverage balance sheet.
Income Statement
47NeutralBalance Sheet
71PositiveCash Flow
28Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 283.98M | 253.11M | 280.95M | 206.15M | 383.88M | 194.93M |
| Gross Profit | 201.60M | 174.46M | 178.04M | 154.94M | 184.43M | 131.29M |
| EBITDA | 96.85M | 23.18M | 20.68M | 3.77M | 22.71M | -9.68M |
| Net Income | 32.64M | 7.80M | 2.14M | -14.01M | 4.00M | -21.86M |
Balance Sheet | ||||||
| Total Assets | 422.35M | 436.02M | 559.67M | 486.23M | 468.51M | 600.04M |
| Cash, Cash Equivalents and Short-Term Investments | 138.16M | 130.83M | 223.86M | 149.91M | 142.12M | 156.71M |
| Total Debt | 77.76M | 66.16M | 84.32M | 125.49M | 87.16M | 123.23M |
| Total Liabilities | 122.15M | 117.05M | 246.22M | 179.57M | 148.91M | 290.16M |
| Stockholders Equity | 300.21M | 318.97M | 313.45M | 306.66M | 319.60M | 309.88M |
Cash Flow | ||||||
| Free Cash Flow | 14.37M | -75.31M | 118.69M | -12.13M | 10.23M | -29.81M |
| Operating Cash Flow | 15.88M | -72.96M | 121.79M | -9.84M | 19.95M | -19.20M |
| Investing Cash Flow | -1.17M | 1.25M | -4.20M | -13.37M | -3.75M | 9.48M |
| Financing Cash Flow | -7.68M | -19.89M | -45.80M | 29.48M | -34.58M | 71.96M |
EBM Technologies Incorporated Peers Comparison
Overall Rating
TW:840948Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| 48Neutral | TWD 568.00M | 47.37 | ― | ― | -31.90% | -73.49% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| TW:8409 | EBM Technologies Incorporated | 18.10 | -3.60 | -16.59% | |
| TW:6665 | Healthconn Corp. | 15.60 | -5.15 | -24.83% | |
| TW:6758 | A-SPINE Asia Co., Ltd. | 29.45 | -8.22 | -21.81% | |
| TW:6999 | Han Biomedical, Inc. | 24.45 | -6.02 | -19.75% | |
| TW:7726 | CARILEX MEDICAL INC. | 32.15 | -3.95 | -10.94% | |
| TW:7835 | H2U Corporation | 14.55 | -25.40 | -63.58% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 09, 2026
